Catalyst Pharmaceuticals Analyst Ratings
Catalyst Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/21/2023 | 75.44% | HC Wainwright & Co. | → $24 | Reiterates | Buy → Buy |
| 06/21/2023 | 75.44% | Truist Securities | $22 → $24 | Maintains | Buy |
| 06/21/2023 | 82.75% | Cantor Fitzgerald | → $25 | Reiterates | Overweight → Overweight |
| 06/20/2023 | 75.44% | Truist Securities | $22 → $24 | Maintains | Buy |
| 05/12/2023 | 75.44% | HC Wainwright & Co. | → $24 | Reiterates | Buy → Buy |
| 03/20/2023 | 75.44% | HC Wainwright & Co. | → $24 | Reiterates | → Buy |
| 01/19/2023 | 60.82% | Truist Securities | $18 → $22 | Maintains | Buy |
| 12/21/2022 | 31.58% | Truist Securities | $17 → $18 | Maintains | Buy |
| 12/21/2022 | 75.44% | HC Wainwright & Co. | $18 → $24 | Maintains | Buy |
| 12/20/2022 | 46.2% | Piper Sandler | $18 → $20 | Maintains | Overweight |
| 08/24/2022 | 13.3% | Roth Capital | $10 → $15.5 | Downgrades | Buy → Neutral |
| 08/11/2022 | 24.27% | Truist Securities | $12 → $17 | Maintains | Buy |
| 08/11/2022 | 31.58% | HC Wainwright & Co. | $12 → $18 | Maintains | Buy |
| 02/08/2022 | -12.28% | HC Wainwright & Co. | $9 → $12 | Maintains | Buy |
| 03/18/2021 | -48.83% | Roth Capital | $6.5 → $7 | Maintains | Buy |
| 08/12/2020 | -41.52% | Truist Securities | $10 → $8 | Maintains | Buy |
| 05/13/2020 | -26.9% | SunTrust Robinson Humphrey | $11 → $10 | Maintains | Buy |
| 02/14/2020 | -12.28% | Cantor Fitzgerald | $11 → $12 | Reiterates | → Overweight |
| 12/13/2018 | -45.18% | Piper Sandler | $5 → $7.5 | Maintains | Overweight |
| 11/29/2018 | -41.52% | Cantor Fitzgerald | → $8 | Reiterates | → Overweight |
| 09/21/2018 | -41.52% | Cantor Fitzgerald | → $8 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 07/21/2023 | 75.44% | HC Wainwright & Co. | → 24 美元 | 重申 | 購買 → 購買 |
| 06/21/2023 | 75.44% | 信託證券 | 22 美元 → 24 美元 | 維護 | 購買 |
| 06/21/2023 | 82.75% | 坎託·菲茨傑拉德 | → 25 美元 | 重申 | 超重 → 超重 |
| 06/20/2023 | 75.44% | 信託證券 | 22 美元 → 24 美元 | 維護 | 購買 |
| 05/12/2023 | 75.44% | HC Wainwright & Co. | → 24 美元 | 重申 | 購買 → 購買 |
| 03/20/2023 | 75.44% | HC Wainwright & Co. | → 24 美元 | 重申 | → 購買 |
| 01/19/2023 | 60.82% | 信託證券 | 18 美元 → 22 美元 | 維護 | 購買 |
| 2022 年 12 月 21 日 | 31.58% | 信託證券 | 17 美元 → 18 美元 | 維護 | 購買 |
| 2022 年 12 月 21 日 | 75.44% | HC Wainwright & Co. | 18 美元 → 24 美元 | 維護 | 購買 |
| 2022 年 12 月 20 日 | 46.2% | 派珀·桑德勒 | 18 美元 → 20 美元 | 維護 | 超重 |
| 2022 年 8 月 24 日 | 13.3% | 羅斯資本 | 10 美元 → 15.5 美元 | 降級 | 買入 → 中性 |
| 08/11/2022 | 24.27% | 信託證券 | 12 美元 → 17 美元 | 維護 | 購買 |
| 08/11/2022 | 31.58% | HC Wainwright & Co. | 12 美元 → 18 美元 | 維護 | 購買 |
| 2022 年 8 月 2 日 | -12.28% | HC Wainwright & Co. | 9 美元 → 12 美元 | 維護 | 購買 |
| 03/18/2021 | -48.83% | 羅斯資本 | 6.5 美元 → 7 美元 | 維護 | 購買 |
| 08/12/2020 | -41.52% | 信託證券 | 10 美元 → 8 美元 | 維護 | 購買 |
| 05/13/2020 | -26.9% | SunTrust 羅賓遜漢弗萊 | 11 美元 → 10 美元 | 維護 | 購買 |
| 02/14/2020 | -12.28% | 坎託·菲茨傑拉德 | 11 美元 → 12 美元 | 重申 | → 超重 |
| 2018 年 12 月 13 日 | -45.18% | 派珀·桑德勒 | 5 美元 → 7.5 美元 | 維護 | 超重 |
| 11/29/2018 | -41.52% | 坎託·菲茨傑拉德 | → 8 美元 | 重申 | → 超重 |
| 09/21/2018 | -41.52% | 坎託·菲茨傑拉德 | → 8 美元 | 啓動覆蓋開啓 | → 超重 |
What is the target price for Catalyst Pharmaceuticals (CPRX)?
Catalyst Pharmicals（CPRX）的目標價格是多少？
The latest price target for Catalyst Pharmaceuticals (NASDAQ: CPRX) was reported by HC Wainwright & Co. on July 21, 2023. The analyst firm set a price target for $24.00 expecting CPRX to rise to within 12 months (a possible 75.44% upside). 13 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年7月21日公佈了Catalyst Pharmicals（納斯達克股票代碼：CPRX）的最新目標股價。這家分析公司將目標股價定爲24.00美元，預計CPRX將在12個月內升至12個月內（可能上漲75.44％）。去年有13家分析公司公佈了評級。
What is the most recent analyst rating for Catalyst Pharmaceuticals (CPRX)?
分析師對Catalyst Pharmicals（CPRX）的最新評級是多少？
The latest analyst rating for Catalyst Pharmaceuticals (NASDAQ: CPRX) was provided by HC Wainwright & Co., and Catalyst Pharmaceuticals reiterated their buy rating.
Catalyst Pharmicals（納斯達克股票代碼：CPRX）的最新分析師評級由HC Wainwright & Co. 提供，Catalyst Pharmicals重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Catalyst Pharmaceuticals (CPRX)?
Catalyst Pharmicals（CPRX）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Catalyst Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Catalyst Pharmaceuticals was filed on July 21, 2023 so you should expect the next rating to be made available sometime around July 21, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與Catalyst Pharmicals的高管和客戶交談以及聽取財報電話會議）後得出了股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Catalyst Pharmicals的最新評級是在2023年7月21日提交的，因此你應該預計下一個評級將在2024年7月21日左右公佈。
Is the Analyst Rating Catalyst Pharmaceuticals (CPRX) correct?
分析師對 Catalyst Pharmicals (CPRX) 的評級正確嗎？
While ratings are subjective and will change, the latest Catalyst Pharmaceuticals (CPRX) rating was a reiterated with a price target of $0.00 to $24.00. The current price Catalyst Pharmaceuticals (CPRX) is trading at is $13.68, which is within the analyst's predicted range.
儘管評級是主觀的，將會發生變化，但最新的Catalyst Pharmicals（CPRX）評級得到了重申，目標股價爲0.00美元至24.00美元。Catalyst Pharmicals（CPRX）目前的交易價格爲13.68美元，在分析師的預測區間內。